Document is current
Any future updates will be listed below
-
Authors
Sarto, Jordi
Esteller-Gauxax, Diana
Guillén, Núria
Falgàs, Neus
Borrego-Écija, Sergi
Massons, Miquel
Fernández-Villullas, Guadalupe
González, Yolanda
Tort-Merino, Adrià
Bosch, Beatriz
Castellví, Magda
Piñol-Ripoll, Gerard
Juncà-Parella, Jordi
del Val, Andrea
Pérez-Millan, Agnès
Comas, Aina
Antonell, Anna
Naranjo, Laura
Ruiz-García, Raquel
Augé, Josep María
Sánchez-Valle, Raquel
Lladó, Albert
Balasa, Mircea https://orcid.org/0000-0002-1795-4228
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (19/00198, 22/00343, 19/00449, 23/00173, 20/00448, CM23/00137, JR22/00014)
Joan Rodés-Josep Baselga-FBBVA
Emili Letang-Josep Font Hospital Clínic grant
- License Information
-
More Information
Article History
Received: 18 October 2024
Revised: 17 December 2024
Accepted: 2 January 2025
First Online: 23 January 2025
Declarations
:
: RSV has served in Advisory Boards Meetings for Wave Life Sciences, Ionis, and Novo Nordisk and received personal fees for participating in educational activities from Janssen, Roche Diagnostics, and Neuroxpharma and funding to her institution for Investigator Initiated studies from Biogen and Sage Pharmaceuticals. The rest of the authors report no relevant disclosures.
: The study protocol was approved by the Hospital Clínic de Barcelona Research Ethics Committee (HCB/2019/0600).
